DOCS Stock Recent News
DOCS LATEST HEADLINES
Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.
I rate Doximity a 'Buy' with a $62 fair value, citing its dominant network among U.S. healthcare professionals and robust growth trajectory. Doximity's strong pharma marketing business, workflow solutions, and AI-driven hiring tools underpin its competitive advantage and long-term expansion potential. The company's debt-free balance sheet, high free cash flow, and substantial share repurchases support its financial health and margin expansion outlook.
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
NEW YORK , June 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company's business and operations.
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.